Regular Article
Inhibition of Platelet Adhesion to Collagen by cGMP-Elevating Agents

https://doi.org/10.1006/bbrc.1996.5998Get rights and content

Abstract

In the present study, we examined the effects and action mechanisms of cGMP-elevating agents on platelet adhesion to collagen fiber. YC-1, a nitric oxide (NO)-independent activator of soluble guanylate cyclase, inhibited both initial and long-term platelet adhesion to collagen, and the inhibitory effect was potentiated by dipyridamole, a selective inhibitor of cGMP-specific phosphodiesterase. Sodium nitroprusside (SNP), a NO-donor, and 8-bromo-cGMP also inhibited the initial platelet adhesion, but inhibited long-term adhesion only in the presence of dipyridamole. Collagen-induced intracellular Ca2+mobilization and actin polymerization were prevented by YC-1, SNP and 8-bromo-cGMP. Since blockade of Ca2+mobilization and actin polymerization caused by collagen led to decrease of platelet adhesion, we suggest that the inhibitory activity of cGMP-elevating agents on the adhesion of platelets to collagen is resulting from interference of these signaling pathways.

References (24)

  • M.W. Radomski et al.

    Biochem. Biophys. Res. Commun.

    (1987)
  • R. Polanowska-Grabowska et al.

    Blood

    (1994)
  • C.C. Wu et al.

    Biochem. Biophys. Res. Commun.

    (1996)
  • F.N. Ko et al.

    Blood

    (1994)
  • C.C. Wu et al.

    Biochem. Biophys. Acta

    (1994)
  • J.E. Fox et al.

    J. Biol. Chem.

    (1989)
  • J.B. Smith et al.

    Anal. Biochem.

    (1990)
  • E.G. Lapetina et al.

    Thromb. Res.

    (1986)
  • B. Haimovich et al.

    J. Biol. Chem.

    (1993)
  • C.C. Lugnier et al.

    Biochem. Pharmocol.

    (1986)
  • T. Nakano et al.

    J. Biol. Chem.

    (1989)
  • Cited by (46)

    • Nitric oxide-enhancing or -releasing agents as antithrombotic drugs

      2019, Biochemical Pharmacology
      Citation Excerpt :

      Dipyridamole (2,6–bis (diethanolamino)–4,8-dipiperidino-pyrimido 5,4-d pyrimidine), synthesized more than fifty years ago and initially used as a coronary vasodilator, inhibits platelet aggregation by acting on multiple targets, and namely by inhibiting the reuptake of adenosine by RBC [108] thus enhancing the circulating levels of this nucleoside which exerts an antiplatelet activity by stimulating platelet adenylylcycalse, by inhibiting PDE5 and PDE3, and by acting as a antioxidant [107]. Dipyridamole potentiates the inhibitory effects of NO on human platelets by inhibiting PDE5, thus enhancing NO-stimulated intraplatelet cGMP [109], enhances the platelet adhesion-suppressing effect of cGMP-elevating agents [110], potentiates the antiplatelet effects of aspirin in whole blood or in the presence of white blood cells [108] and increases cGMP-mediated platelet VASP phosphorylation confirming the preeminent role of NO in its action [111]. Dipyridamole potentiated the beneficial effects of adenosine on ischemia/reperfusion damage-induced myocardial dysfunction in guinea pigs by inhibiting platelet adhesion [112] and strongly potentiated the antithrombotic properties of inhaled NO in a canine model of platelet-mediated coronary artery thrombosis without prolonging the bleeding time [113].

    • Neuroprotective potential of high-dose biotin

      2017, Medical Hypotheses
      Citation Excerpt :

      All of the rats who received saline without biotin experienced strokes, whereas none in the biotin group did; mortality in the former group was 40%, but none of the biotin-treated rats died. It is well known that NO exerts a stabilizing effect on platelets, and also inhibits their adhesion to collagen; this effect is known to be mediated by cGMP [76–78]. It is therefore reasonable to suspect that high-dose biotin could likewise stabilize platelets; potentially this phenomenon might have contributed to the absence of stroke in the biotin-treated hypertensive rats.

    • YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages

      2012, Toxicology and Applied Pharmacology
      Citation Excerpt :

      3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1), an NO-independent and heme-dependent sGC activator, also sensitizes sGC to NO and carbon monoxide (CO) (Friebe et al., 1996, 1998; Ko et al., 1994). Through activation of sGC, YC-1 shows versatile pharmacological functions including inhibiting platelet aggregation and adhesion (Friebe et al., 1998; Wu et al., 1995, 1997), as well as decreasing vascular smooth muscle proliferation and contractions (Mulsch et al., 1997; Tulis, 2008). However, several studies showed that YC-1 exhibits several additional effects that do not involve the sGC/cGMP pathway.

    • Measurement of adhesion of human platelets in plasma to protein surfaces in microplates

      2005, Journal of Pharmacological and Toxicological Methods
    • Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3

      2004, Biochemical Pharmacology
      Citation Excerpt :

      In combination with SNP, general PDE inhibition (papaverine) and PDE5 inhibition (dipyridamole, zaprinast, sildenafil) further raised the cGMP level, with zaprinast and sildenafil being most active. A similar, minor increase in cGMP by dipyridamole alone but high increase upon simultaneous guanylate cyclase activation has also been observed by others [29]. Typically, the type-3/4 inhibitor zardaverine also caused cGMP elevation in this case.

    View all citing articles on Scopus
    1

    Address for correspondence: Dr. Che-Ming Teng, Pharmacological Institute, College of Medicine, National Taiwan University, No. 1, Jen-Ai Rd., 1st Section, Taipei, 10018, Taiwan. Fax: 886-2-322-1742.

    View full text